# Dietitian-led weight-loss programmes in HR-positive breast cancer

Source: https://onco.cc/technologies/dietitian-led-weight-loss-breast/  
OnCo record `dietitian-led-weight-loss-breast` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Being overweight after breast cancer is linked with more recurrence, so a 3,000-woman trial tested a two-year telephone weight-loss programme. Women lost weight, but the trial did not clearly show fewer recurrences.

## Summary

Obesity at diagnosis is associated with roughly 30% higher breast cancer mortality in meta-analyses, and with reduced aromatase inhibitor efficacy, making intentional weight loss an attractive adjuvant strategy. The Breast Cancer Weight Loss (BWEL, Alliance A011401) trial randomised 3,181 women with stage II-III HR-positive or HER2-positive breast cancer and BMI at least 27 to a two-year telephone-based lifestyle intervention (calorie restriction, 150-225 minutes of activity a week, health coaching) plus health education, or health education alone, with invasive disease-free survival as the primary endpoint. The intervention produced clinically meaningful weight loss at one and two years; primary results presented in late 2025 were reported as not showing a statistically significant iDFS improvement at the primary analysis, with longer follow-up and subgroup analyses to come (see trial record for caveats). Whether that reflects insufficient weight loss, too short a follow-up, or a true absence of effect is now the central question, and pharmacological weight loss with GLP-1 receptor agonists is the obvious next test. Weight-loss programmes remain justified for cardiometabolic health, fitness and quality of life in survivors.

## Fields

- Kind: Technology
- Status: phase-3
- Last checked: 2026-09-08
- Principle: Reducing adiposity lowers aromatase-driven oestrogen synthesis, insulin, leptin and inflammatory cytokines that promote growth of hormone-dependent residual disease.
- Strengths: Large, well-run pragmatic trial answered a long-standing question; Telephone delivery is scalable; Weight loss achieved was real
- Limitations: Primary cancer endpoint not met at first analysis; Weight loss of a few percent may be below the biological threshold; Adherence and attrition over two years

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Weight_loss
- ClinicalTrials.gov NCT02750826: https://clinicaltrials.gov/study/NCT02750826
- BWEL design paper (npj Breast Cancer 2017): https://doi.org/10.1038/s41523-017-0040-8

## Connected records

- ideas: [GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer](https://onco.cc/ideas/idea-nl-glp1-adjuvant-hr-breast/)
- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- fronts: [Diet, Exercise & Lifestyle](https://onco.cc/fronts/nutrition-lifestyle/), [Hormonal Therapy](https://onco.cc/fronts/hormonal/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/), [Exercise & lifestyle oncology](https://onco.cc/technologies/exercise-oncology/), [GLP-1 receptor agonists and obesity-related cancer risk](https://onco.cc/technologies/glp1-agonists-cancer-risk/), [Structured exercise programmes after curative treatment](https://onco.cc/technologies/structured-exercise-survivorship/)
- drugs: [Exemestane](https://onco.cc/drugs/exemestane/), [Letrozole (and other aromatase inhibitors)](https://onco.cc/drugs/letrozole/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)
- terms: [Body composition (lean mass, fat mass, visceral fat)](https://onco.cc/terms/body-composition/), [Energy balance](https://onco.cc/terms/energy-balance/), [Obesity-related cancers (IARC list of 13)](https://onco.cc/terms/obesity-related-cancers/)
- trials: [BWEL (Breast Cancer Weight Loss, Alliance A011401)](https://onco.cc/trials/bwel/), [WHEL (Women's Healthy Eating and Living)](https://onco.cc/trials/whel/)
- bottlenecks: [Failures are hidden](https://onco.cc/bottlenecks/b-negative-results/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/)
- key papers: [Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design](https://onco.cc/key-papers/paper-ligibel-npj-breast-cancer/)
- pathways: [Lipid synthesis, uptake & cholesterol](https://onco.cc/pathways/lipid-metabolism-cancer/)
- roadmaps: [Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment](https://onco.cc/roadmaps/nutrition-lifestyle-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/dietitian-led-weight-loss-breast.json